USE OF PERLECAN DOMAIN V IN TREATING AMYLOIDOGENIC DISEASE
摘要
<p>The application reports that perlecan domain V (DV) or the LG3 domain thereof reduces deposition and toxicity of Aß peptide, the major component of plaques in Alzheimer's disease. Methods of using DV, LG3 and related molecules in treatment of amyloidogenic diseases, particularly Alzheimer's disease, are provided.</p>
申请公布号
WO2011085136(A9)
申请公布日期
2012.08.02
申请号
WO2011US20426
申请日期
2011.01.06
申请人
ELAN PHARMACEUTICALS, INC.;THE TEXAS A&M UNIVERSITY SYSTEM;BIX, GREGORY;WRIGHT, SARAH;GRISWOLD-PRENNER, IRENE
